Trial Profile
Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Fluorouracil
- Indications Nasopharyngeal cancer
- Focus Adverse reactions
- 01 May 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Nov 2010 New trial record